TrialChinese medical journal2020

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.

Bin Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.